The estimated Net Worth of Allan Reine is at least $499 millier dollars as of 9 August 2021. Dr Reine owns over 26,892 units of Foghorn Therapeutics stock worth over $498,578 and over the last 7 years he sold FHTX stock worth over $0.
Dr has made over 2 trades of the Foghorn Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 26,892 units of FHTX stock worth $100,038 on 9 August 2021.
The largest trade he's ever made was buying 65,000 units of Foghorn Therapeutics stock on 16 August 2017 worth over $313,300. On average, Dr trades about 10,210 units every 162 days since 2017. As of 9 August 2021 he still owns at least 53,784 units of Foghorn Therapeutics stock.
You can see the complete history of Dr Reine stock trades at the bottom of the page.
Dr. Allan Reine is the Chief Financial Officer at Foghorn Therapeutics.
Dr Reine is 46, he's been the Chief Financial Officer of Foghorn Therapeutics since . There are 5 older and 2 younger executives at Foghorn Therapeutics. The oldest executive at Foghorn Therapeutics Inc. is Dr. Douglas G. Cole M.D., 61, who is the Founder & Chairman.
Allan's mailing address filed with the SEC is 500 TECHNOLOGY SQUARE, STE #700, CAMBRIDGE, MA, 02139.
Over the last 4 years, insiders at Foghorn Therapeutics have traded over $262,160 worth of Foghorn Therapeutics stock and bought 305,500 units worth $4,888,000 . The most active insiders traders include Adam Koppel, Ian F Smith et B Lynne Parshall. On average, Foghorn Therapeutics executives and independent directors trade stock every 109 days with the average trade being worth of $663,343. The most recent stock trade was executed by Steven F. Bellon on 9 September 2024, trading 20,000 units of FHTX stock currently worth $190,000.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. Foghorn Therapeutics Inc. has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel therapeutics based on disruptors of a specified transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Foghorn Therapeutics executives and other stock owners filed with the SEC include: